Document is current
Any future updates will be listed below
-
Authors
Naeem, Abdul
Waseem, Arshi
Khan, Mohsin Ali
Robertson, Avril AB.
Raza, Syed Shadab
- License Information
-
More Information
Article History
Received: 15 July 2024
Accepted: 4 December 2024
First Online: 20 December 2024
Declarations
:
: This study was approved by the Experimental Animal Ethical Committee of Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India (IAEC/ELMCH/1/23/-2).
: Not Applicable.
: Not Applicable.
: AABR is an inventor of intellectual property (WO2016131098, WO2017140778, WO2018215818), granted in multiple jurisdictions, which discloses NLRP3 inhibitors for treatment of inflammatory diseases. These patents are licensed to Inflazome Ltd., which sold to Roche in 2020, and the compounds disclosed are progressing through clinical trials.
